Click image to enlarge
The
U-PLEX platform offers validated components that can be combined to create high quality assays quickly and easily. The U-PLEX PlGF Antibody Set is a matched pair of antibodies that can be used (with other U-PLEX components such as plates, calibrators, diluents, and MSD GOLD Read Buffer B) to build U-PLEX assays that measure PlGF. These assays can measure PlGF alone or in multiplex panels with other biomarkers. The Product Inserts in the “Documentation” tab (below) provide detailed instructions for building assays with U-PLEX Antibody Sets.
For information on multiplexing PlGF with other analytes, please see
Immuno-Oncology Group 1 Human Assays.
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
Analyte(s)
|
|
PlGF
|
|
Species
|
|
Human
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
Storage Condition
|
|
2-8 °C
|
|
Schedule B Code
|
|
3822.19.0000
|
|
Product Description
|
Storage
|
Quantity per Kit
|
Biotin Human PlGF Antibody, 1 Plate
|
2-8 °C
|
1 vial (1 plate size)
|
|
SULFO-TAG Human PlGF Antibody, 1 Plate
|
2-8 °C
|
1 vial (1 plate size)
|
|
Product Description
|
Storage
|
Quantity per Kit
|
Biotin Human PlGF Antibody, 5 Plate
|
2-8 °C
|
1 vial (5 plate size)
|
|
SULFO-TAG Human PlGF Antibody, 5 Plate
|
2-8 °C
|
1 vial (5 plate size)
|
|
Product Inserts
|
|
|
Datasheets
|
|
|
Product Highlights
|
|
|
SDS
|
|
|
Title
|
Journal
|
Year
|
|
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2 in patients with advanced hepatocellular cancer.
|
|
|
|
Phase I study of Dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
|
|
|
|
Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948).
|
|
|
|
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel anti-angiogenesis agent, in two phase I trials in patients with advanced solid tumors.
|
|
|
|
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters